Cancer News and Research

Latest Cancer News and Research

Reprogrammed herpes virus can improve early cancer diagnosis

Scientists have used a genetically re-engineered herpes virus that selectively hunts down and infects cancerous tumors and then delivers genetic material that prompts cancers to secrete a biomarker and reveal their presence.

12 May 2011

Researcher finds ultrasound as effective as CT scans for head and neck diagnoses

For diagnosing head and neck ailments, tests that use radiation are always less desirable than those that don't. Otolaryngologists have a wide range of techniques available to them, including CT or "CAT" scans, MRI and ultrasound.

12 May 2011

Being mildly overweight benefits ALS patients

Patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, may be an exception to the rule that being overweight is a health hazard. In a retrospective study of over 400 ALS patients, Massachusetts General Hospital researchers found that those who were mildly obese survived longer than patients who were normal weight, underweight or even overweight.

12 May 2011

Neogenix Oncology to receive European Patent for NEO-301 antibody for treatment of pancreatic cancer

Neogenix Oncology is pleased to announce that it will be granted a European Patent relating to its NEO-301 antibody, to take effect beginning September 23, 2011.

12 May 2011

FDA accepts Insys NDA for Fentanyl SL Spray to treat breakthrough cancer pain

Insys Therapeutics, Inc. today announced that the Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for Fentanyl SL Spray. The FDA will notify Insys of its PDUFA date in the 74-day letter which is expected in the upcoming weeks.

12 May 2011

ViroPharma, Halozyme sign license deal to develop Cinryze against hereditary angioedema

Halozyme Therapeutics, Inc. and ViroPharma Incorporated, today announced the signing of a worldwide exclusive licensing agreement for the use of rHuPH20 in the development of a subcutaneous formulation of Cinryze .

12 May 2011

Santaris Pharma advances SPC4955 into Phase 1 trial for high cholesterol treatment

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies, today announced that it has advanced a second drug from its cardiometabolic program, SPC4955 into Phase 1 clinical trials, for the treatment of high cholesterol.

11 May 2011

ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, the Centre Léon Bérard, the major cancer research and treatment center for the Rhône-Alpes region of France, and ImmunID Technologies SAS, a diagnostic company specialized in innovative immunomonitoring tests and services, today announced initiation of a Phase IIa clinical trial that will evaluate multiple combinations of recombinant human interleukin-7, the investigational multifunctional cytokine under development by Cytheris, and a chemotherapeutic agent, XELODA, in the treatment of metastatic breast cancer.

11 May 2011

SAFC, Oncolytics Biotech sign commercial supply agreement for REOLYSIN

Oncolytics Biotech Inc. today announced that it has entered into a commercial supply agreement with SAFC, a Division of Sigma-Aldrich Corporation, for the commercial manufacture of REOLYSIN, Oncolytics proprietary reovirus.

11 May 2011

Symphogen to present second-generation Sympress platform at ESACT conference

Symphogen, a private biopharmaceutical company developing superior antibody therapeutics to treat cancer, infectious and autoimmune diseases, announced today that second-generation enhancements to the company's SYMPRESS manufacturing and quality control platform will be presented in an oral presentation entitled "Recombinant antibody mixtures; optimization of cell line generation and single-batch manufacturing processes" by Dr. Søren K. Rasmussen, Principal Scientist, Symphogen at the upcoming European Society for Animal Cell Technology conference in Vienna on May 17, 2011.

11 May 2011

Study: Many patients screened for colon cancer more often than recommended

Many patients are getting screened for colorectal cancer more often than guidelines recommend, hints a new study.

11 May 2011

Common tiny tropical fish plays a key role in new model for Cushing disease

A common, tiny tropical fish plays a key role in a new model for Cushing disease, giving researchers a powerful tool to conduct extensive searches for effective treatments for this serious hormonal disorder, testing up to 300 drugs weekly.

11 May 2011

Journal of Rheumatology publishes positive results from Cimzia Phase III trial in RA

UCB announced today results from a post hoc analysis of the RAPID 1 study published in the Journal of Rheumatology. The results suggest moderate to severe rheumatoid arthritis patients treated with Cimzia, the only approved PEGylated anti-TNF, together with methotrexate, achieved a rapid response associated with improved long-term outcomes one year after treatment began.

11 May 2011

Majority of urban NYC women with hepatitis B do not receive education, subsequent care

According to new research at Columbia Presbyterian Medical Center, high rates of chronic hepatitis B infection are found in pregnant minority and immigrant women in the New York City area, and most of them do not receive education, appropriate follow-up testing or referral, which is considered the standard of care for all persons newly identified as HBV carriers.

11 May 2011

Inovio first quarter total revenue increases to $3.1 million for 2011

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2011.

11 May 2011

Adherence to disease-modifying drugs is low in patients with multiple sclerosis

Disease-modifying drugs (DMDs) are injected medications used to slow the progression of multiple sclerosis, and have been shown to reduce the frequency and severity of relapses. But according to a new study led by St. Michael's Hospital and the Institute for Clinical Evaluative Sciences, adherence to all DMDs is low, with less than half of patients, or 44 per cent, continually adherent after two years.

11 May 2011

Women with invasive breast cancer can benefit from new genomic test

A new genomic test combining multiple signatures - a patient's estrogen receptor status, endocrine therapy response, chemotherapy resistance and sensitivity - shows promise as a predictor of chemotherapy response and survival benefit in women with invasive breast cancer, according to research led by The University of Texas MD Anderson Cancer Center.

11 May 2011

Genentech submits vemurafenib NDA for BRAF V600 mutation-positive metastatic melanoma

Genentech, a member of the Roche Group, today announced that the company submitted a New Drug Application for vemurafenib to the U.S. Food and Drug Administration for people with BRAF V600 mutation-positive metastatic melanoma, and that Roche submitted a Marketing Authorization Application to the European Medicines Agency for vemurafenib in the same indication.

11 May 2011

BioAlliance Pharma enters license deal with Sosei to commercialize Loramyc in Japan

BioAlliance Pharma, a company dedicated to specialty and orphan pharma products in oncology and supportive care, today announced that it has entered into an exclusive licensing agreement with Sosei Co. Ltd. for commercialization rights in Japan for Loramyc muco-adhesive buccal tablet.

11 May 2011

Novel ultrasound-targeted microbubble-destruction technology advances cure for prostate cancer

Cancer researchers are a step closer to finding a cure for advanced prostate cancer after effectively combining an anti-cancer drug with a viral gene therapy in vivo using novel ultrasound-targeted microbubble-destruction (UTMD) technology.

11 May 2011

Cancer News and Research

Latest Cancer News and Research

Reprogrammed herpes virus can improve early cancer diagnosis

Researcher finds ultrasound as effective as CT scans for head and neck diagnoses

Being mildly overweight benefits ALS patients

Neogenix Oncology to receive European Patent for NEO-301 antibody for treatment of pancreatic cancer

FDA accepts Insys NDA for Fentanyl SL Spray to treat breakthrough cancer pain

ViroPharma, Halozyme sign license deal to develop Cinryze against hereditary angioedema

Santaris Pharma advances SPC4955 into Phase 1 trial for high cholesterol treatment

ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer

SAFC, Oncolytics Biotech sign commercial supply agreement for REOLYSIN

Symphogen to present second-generation Sympress platform at ESACT conference

Study: Many patients screened for colon cancer more often than recommended

Common tiny tropical fish plays a key role in new model for Cushing disease

Journal of Rheumatology publishes positive results from Cimzia Phase III trial in RA

Majority of urban NYC women with hepatitis B do not receive education, subsequent care

Inovio first quarter total revenue increases to $3.1 million for 2011

Adherence to disease-modifying drugs is low in patients with multiple sclerosis

Women with invasive breast cancer can benefit from new genomic test

Genentech submits vemurafenib NDA for BRAF V600 mutation-positive metastatic melanoma

BioAlliance Pharma enters license deal with Sosei to commercialize Loramyc in Japan

Novel ultrasound-targeted microbubble-destruction technology advances cure for prostate cancer

Industry Focus eBook - Oncology (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Oncology (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in